Latest Breaking News On - Lumbar interbody fusion - Page 1 : comparemela.com

Global Spinal Fusion Industry is anticipated to witness a 5 4% CAGR, possibly attaining US$ 16,771 8 Million by 2033 | FMI

Global Spinal Fusion Industry is anticipated to witness a 5 4% CAGR, possibly attaining US$ 16,771 8 Million by 2033 | FMI
fmiblog.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fmiblog.com Daily Mail and Mail on Sunday newspapers.

United statesNew yorkShandong weigao group medical polymer companyIntegra lifesciences holdings corpMicroport scientific corporationZimmer biomet holdings incBonovo orthopedics incGreater new york chamberSurgical centersStryker corporation incCentinel spine incKey companiesWenzel spine incYm incConsumer technologyJohnson services inc depuy synthes

200+ spine medtech FDA clearances in 2023

The Food and Drug Administration cleared more than 200 spine-related devices and technologies with 510(k) approval in 2023.

United statesKisar stratfordCagefrom strykerUnivy osteovyMedtronic sofamor danekAscential ibd peekcDouble medical technologyShanghai sanyou medical coKj consulting corpMedacta internationalPioneer surgical technologyDrug administrationCranial guidance softwareMedos internationalSpine truss systemVertebral body replacement device

Ageing Population and Rising Prevalence of Spine Disorders to Drive Spinal Fusion Market to Reach US$ 16,771 8 Million by 2033 at a CAGR of 5 4%

Ageing Population and Rising Prevalence of Spine Disorders to Drive Spinal Fusion Market to Reach US$ 16,771 8 Million by 2033 at a CAGR of 5 4%
fmiblog.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fmiblog.com Daily Mail and Mail on Sunday newspapers.

United statesNew yorkKey companiesShandong weigao group medical polymer companyYm incMicroport scientific corporationBonovo orthopedics incStryker corporation incCentinel spine incWenzel spine incMedtronic plcZimmer biomet holdings incGreater new york chamberExactech incOrthofix holdings incJohnson services inc depuy synthes

Kuros Biosciences AG: Kuros Biosciences Announces Completion of Enrollment in the Fibrin-PTH Phase 2 Trial

Kuros Biosciences AG: Kuros Biosciences Announces Completion of Enrollment in the Fibrin-PTH Phase 2 Trial
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United statesJohn chiMary ann changKuros biosciencesR todd allenDaniel geigerDrug administrationNews serviceSwiss exchangeBiosciences announces completionChief executive officerInvestigational new drugLumbar interbody fusionDie experten

Kuros Biosciences Completes Enrollment of Randomized Stage of Phase 2 Trial for Fibrin-PTH

Kuros Biosciences AG / Key word(s): Miscellaneous Kuros Biosciences Completes Enrollment of Randomized Stage of Phase 2 Trial for Fibrin-PTH 23.11.2022 / 07:00 CET/CEST First investigational trial of drug-biologic bone graft for spinal fusion No drug-related Serious Adverse Events (SAEs) reporte.

United statesKuros biosciencesMichael grauDrug administrationNews serviceSwiss exchangeBiosciences completes enrollmentRandomized stageSerious adverse eventsInvestigational new drugChief executive officerSci advisorsLumbar interbody fusionStage ofIbrin pthEt cest